Oxybutynin

Summary

Oxybutynin (CHEMBL1231) is an approved small molecule (ATC G04BD04) targeting CHRM1, CHRM2, and CHRM3; indicated across 14 conditions including overactive bladder and polyneuropathy.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G04BD04
• Targets: 5 (CHRM1, CHRM2, CHRM3…)
• Indications: 14 conditions
• Clinical trials: 68
• Chemistry: 357.5 Da · C22H31NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1231
Name	Oxybutynin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	4634
ChEBI	CHEBI:144551
ATC	G04BD04
Molecular formula	C22H31NO3
Molecular weight	357.5
InChIKey	XIQVNETUBQGFHX-UHFFFAOYSA-N

SMILES: CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O

IUPAC name: 4-(diethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate

ChEBI definition: A carboxylic ester resulting from the formal condensation of the carboxy group of cyclohexyl(hydroxy)phenylacetic acid with the hydroxy group of 4-(diethylamino)but-2-yn-1-ol.

Also known as: Contimin 2.5, Contimin 5, Cystrin, Kentera, Lyrinel xl, Oxibutinina, Oxybutynin, Oxybutynine, Oxytrol, Oxytrol for women, Promictuline, Urimin

Parent form; salt/anhydrous children: CHEMBL1133

Patent coverage: 4,139 distinct patent families (15,072 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CHRM1	M1 receptor	Antagonist	8.6	0.2%	P11229
CHRM2	M2 receptor	Antagonist	8.1	0%	P08172
CHRM3	M3 receptor	Antagonist	8.8	0%	P20309
CHRM4	M4 receptor	Antagonist	8.7	1.6%	P08173
CHRM5	M5 receptor	Antagonist	7.9	0%	P08912

Broader ChEMBL bioactivity targets: 23 (assay-derived). Sample: Muscarinic acetylcholine receptor M4, 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, Muscarinic acetylcholine receptor M5, Estrogen receptor, Thromboxane A2 receptor, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, Sodium-dependent noradrenaline transporter, Alpha-1A adrenergic receptor.

Bioactivity

ChEMBL activities: 42 potent at pChembl ≥ 5 of 55 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CHRM4	9.56	Ki	0.28	nM	CHEMBL_ACT_7744648
CHRM3	9.24	Ki	0.57	nM	CHEMBL_ACT_7744646
CHRM3	9.11	Ki	0.78	nM	CHEMBL_ACT_1960490
CHRM1	9.07	Ki	0.85	nM	CHEMBL_ACT_7744642
P08483	9.02	Ki	0.95	nM	CHEMBL_ACT_1518939
CHRM1	9	Ki	1	nM	CHEMBL_ACT_1960440
CHRM3	8.89	Ki	1.3	nM	CHEMBL_ACT_1666530
CHRM3	8.82	Ki	1.51	nM	CHEMBL_ACT_10927294
CHRM4	8.7	IC50	1.99	nM	CHEMBL_ACT_7744647
CHRM5	8.63	Ki	2.31	nM	CHEMBL_ACT_7744650
CHRM1	8.62	Ki	2.4	nM	CHEMBL_ACT_10927324
CHRM3	8.57	IC50	2.71	nM	CHEMBL_ACT_7744645
CHRM5	8.49	IC50	3.22	nM	CHEMBL_ACT_7744649
CHRM1	8.45	IC50	3.52	nM	CHEMBL_ACT_7744641
CHRM4	8.44	Ki	3.63	nM	CHEMBL_ACT_10927279
P08483	8.28	Ki	5.3	nM	CHEMBL_ACT_1613264
CHRM1	8.28	AC50	5.2	nM	CHEMBL_ACT_25210340
P08482	8.23	Ki	5.9	nM	CHEMBL_ACT_1613260
P10980	8.16	Ki	6.97	nM	CHEMBL_ACT_1518940
CHRM2	8.09	Ki	8.1	nM	CHEMBL_ACT_1960464
CHRM2	8.05	AC50	9	nM	CHEMBL_ACT_25195885
CHRM2	8.02	Ki	9.61	nM	CHEMBL_ACT_7744644
SIGMAR1	7.99	Ki	10.2	nM	CHEMBL_ACT_7744738
CHRM2	7.93	Ki	11.75	nM	CHEMBL_ACT_10927309
CHRM5	7.85	Ki	14.13	nM	CHEMBL_ACT_10927264
P10980	7.85	Ki	14	nM	CHEMBL_ACT_1613263
CHRM2	7.8	Ki	16	nM	CHEMBL_ACT_1666566
SIGMAR1	7.62	IC50	24.2	nM	CHEMBL_ACT_7744737
CHRM2	7.57	IC50	27	nM	CHEMBL_ACT_7744643
CHRM2	7.4	Kd	39.81	nM	CHEMBL_ACT_1666601

Target pathways

Aggregated over 5 target gene(s): CHRM1, CHRM2, CHRM3, CHRM4, CHRM5.

Top Reactome pathways

17 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	5	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
Signaling by GPCR	5	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
Class A/1 (Rhodopsin-like receptors)	5	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
Amine ligand-binding receptors	5	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
GPCR downstream signalling	5	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
Muscarinic acetylcholine receptors	5	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
GPCR ligand binding	5	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
G alpha (q) signalling events	3	CHRM1, CHRM3, CHRM5
G alpha (i) signalling events	2	CHRM2, CHRM4
Metabolism	1	CHRM3
Integration of energy metabolism	1	CHRM3
Membrane Trafficking	1	CHRM2
Acetylcholine regulates insulin secretion	1	CHRM3
Regulation of insulin secretion	1	CHRM3
Vesicle-mediated transport	1	CHRM2
Cargo recognition for clathrin-mediated endocytosis	1	CHRM2
Clathrin-mediated endocytosis	1	CHRM2

Dominant GO biological processes

GO term	Targets
signal transduction	5
G protein-coupled receptor signaling pathway	5
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	5
G protein-coupled acetylcholine receptor signaling pathway	5
chemical synaptic transmission	5
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	3
nervous system development	3
acetylcholine receptor signaling pathway	3
regulation of locomotion	2
saliva secretion	2
regulation of smooth muscle contraction	2
phospholipase C-activating G protein-coupled receptor signaling pathway	1
neuromuscular synaptic transmission	1
positive regulation of monoatomic ion transport	1

Indications & clinical

Indications

14 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
overactive bladder	4	MONDO:0006624	EFO:1000781
polyneuropathy	3	MONDO:0001824	EFO:0009562
enuresis	3	MONDO:0024290	MONDO:0024290
breast neoplasm	3	MONDO:0021100	MONDO:0007254
seasonal allergic rhinitis	2	MONDO:0005324	EFO:0003956
obstructive sleep apnea syndrome	2	MONDO:0007147	EFO:0003918
sleep apnea syndrome	2	MONDO:0005296	EFO:0003877
reproductive system disorder	2	MONDO:0005039	EFO:0000512

6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 68.

Phase distribution

Phase	Trials
Not specified	17
PHASE3	15
PHASE2	12
PHASE4	11
PHASE1	10
PHASE1/PHASE2	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00224016	PHASE4	COMPLETED	Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition
NCT00224029	PHASE4	COMPLETED	A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition
NCT00613327	PHASE4	COMPLETED	An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants
NCT01126424	PHASE4	COMPLETED	A Study to Compare Two Medications With an Inactive Medication and Look at the Effect on a Person’s Mental Ability
NCT01192568	PHASE4	COMPLETED	Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder
NCT01310712	PHASE4	COMPLETED	Use of Oxybutynin for Treating Hyperhidrosis: A Placebo-control Study
NCT01423838	PHASE4	UNKNOWN	Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder
NCT01899794	PHASE4	COMPLETED	Efficacy of a Combined Surgical and Pharmacological Therapy to Treat Mixed Urinary Incontinence.
NCT03877289	PHASE4	COMPLETED	Efficacy of Oxybutynin in Paediatric Cystitis
NCT04090190	PHASE4	COMPLETED	Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics
NCT04909255	PHASE4	UNKNOWN	Beta-3 Agonist and Anti-muscarinic Agent for Sjogren’s Syndrome With Overactive Bladder
NCT03952299	PHASE3	RECRUITING	Oxybutynin for Post-surgical Bladder Pain and Urgency
NCT06106529	PHASE3	RECRUITING	REDucing Hot FLASHes in Women Using Endocrine Therapy.
NCT06737016	PHASE3	RECRUITING	Efficacy and Safety of Tamsulosin for Children with Posterior Urethral Valve.
NCT00269724	PHASE3	COMPLETED	A Study to Evaluate the Safety and Efficacy of OROS® Oxybutynin Chloride for the Treatment of Urge Urinary Incontinence
NCT00293839	PHASE3	COMPLETED	Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder
NCT00304499	PHASE3	COMPLETED	Efficacy and Safety of OROS Oybutynin and TTS Oxybutynin in Middle-Aged and Elderly Women With Urinary Incontinence
NCT00338624	PHASE3	COMPLETED	An Effectiveness and Safety Study Comparing Oxybutynin Chloride Plus FLOMAX (Tamsulosin HCl) and Placebo Plus FLOMAX (Tamsulosin HCl) for the Treatment of Lower Urinary Tract Symptoms.
NCT00909181	PHASE3	COMPLETED	Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence
NCT01187498	PHASE3	COMPLETED	Behavioral Treatment of Overactive Bladder in Men
NCT01557244	PHASE3	COMPLETED	A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition
NCT01716624	PHASE3	COMPLETED	Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder
NCT01855256	PHASE3	COMPLETED	Treatment of Hyperhidrosis With Oxybutynin
NCT02099695	PHASE3	WITHDRAWN	Evaluate the Efficacy of Oxybutynin Chloride in Patients With Primary Hyperhidrosis
NCT02538302	PHASE3	COMPLETED	Minirin Versus Oxybutynin for Nocturnal Enuresis in Children
NCT02961790	PHASE3	COMPLETED	Oxybutynin Chloride in Managing Hot Flashes
NCT05102396	PHASE2	RECRUITING	Topical Oxybutynin for Treatment of Hyperidrosis: Local or Systemic Effect?
NCT00170768	PHASE2	COMPLETED	Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over
NCT00749632	PHASE2	COMPLETED	A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence
NCT00816972	PHASE2	COMPLETED	Desloratadine With Oxybutynin for the Treatment of Seasonal Allergic Rhinitis and Post-Nasal Drip (Study P04258)(COMPLETED)
NCT00990886	PHASE2	COMPLETED	The Effect of Extended-Release Oxybutynin Chloride on Vasomotor Symptoms in Healthy Post-Menopausal Women
NCT01370811	PHASE2	COMPLETED	A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson’s Disease
NCT02240459	PHASE2	COMPLETED	A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment
NCT02908529	PHASE1/PHASE2	COMPLETED	Atomoxetine and Oxybutynin in Obstructive Sleep Apnea
NCT03187795	PHASE2	UNKNOWN	Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury
NCT03919955	PHASE2	COMPLETED	A Novel Pharmacological Therapy for Obstructive Sleep Apnea
NCT04526353	PHASE2	UNKNOWN	Early Oxybutinin Treatment for Boys With Posterior Urethral Valves
NCT04600336	PHASE2	COMPLETED	Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer
NCT05550246	PHASE1/PHASE2	UNKNOWN	Identifying Sleep Apnea Patients That Best Respond to Atomoxetine Plus Oxybutynin Therapy
NCT06181591	PHASE2	UNKNOWN	A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

576 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
ACLIDINIUM BROMIDE	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CLOZAPINE	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
GENTIAN VIOLET	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
Mavorixafor	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
OLANZAPINE	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
ACETYLCHOLINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
AMIODARONE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
AMOXAPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
ATROPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
BENZTROPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
BETHANECHOL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CARBACHOL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CARBAMOYLCHOLINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CHLOROQUINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CINNARIZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CLEMASTINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CLIDINIUM	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CYCLIZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CYPROHEPTADINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DARIFENACIN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DESLORATADINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DEXCHLORPHENIRAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DICYCLOMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DIMENHYDRINATE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DIPHENHYDRAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DIPHENIDOL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DOXEPIN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
EBASTINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
GLYCOPYRRONIUM BROMIDE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
HALOPERIDOL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
HOMATROPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
HYDROXYCHLOROQUINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
IMIPRAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
IPRATROPIUM	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
KETOTIFEN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
LOXAPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
MAPROTILINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
MEPAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
METHSCOPOLAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
METHSCOPOLAMINE BROMIDE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
MIANSERIN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
NORTRIPTYLINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
ORPHENADRINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PAROXETINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PERHEXILINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PILOCARPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PIRENZEPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PROCHLORPERAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PROMAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PROMETHAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
QUETIAPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
QUINACRINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
RISPERIDONE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
SCOPOLAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
SERTRALINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
SOLIFENACIN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5